Valuation : China Isotope & Radiation Corporation

Market Cap 454.51Cr 530.35Cr 68Cr 58Cr 55Cr 50Cr 94Cr 6.39TCr 94Cr 650.69Cr 252.53Cr 3.27TCr 253.96Cr 248.4Cr 11TCr P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 466.39Cr 544.22Cr 69Cr 60Cr 56Cr 51Cr 96Cr 6.56TCr 97Cr 667.7Cr 259.13Cr 3.35TCr 260.6Cr 254.9Cr 11TCr EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
28/08 China Isotope & Radiation Corporation Announces Resignation of Zhang Junqi as an Executive Director, A Member of the Strategy Committee of the Board and A Member of the Science and Technology Innovation Committee of the Board, Effective August 28, 2026 CI
28/08 China Isotope & Radiation Corporation Announces CEO Changes, Effective August 28, 2026 CI
06/07 China Isotope to Form JV With Associate MT
03/07 China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan CI
18/06 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
18/06 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
27/05 China Isotope Proposes Auditor Change MT
26/05 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
27/03 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
27/03 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
27/03 China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
19/03 China Isotope & Radiation to buy 51% stake in Hunan Huifeng Engineering Detection RE
14/03 China Isotope & Radiation Corporation, Zhonghe Headway and the People?s Government of Maoming Municipality Enter Strategic Cooperation Agreement CI
1 day-5.25%
1 week-7.70%
Current month-5.53%
1 month-7.75%
3 months-14.25%
6 months-24.83%
Current year-22.23%
1 week 15.56
Extreme 15.56
17.49
1 month 15.56
Extreme 15.56
17.98
Current year 15.56
Extreme 15.56
24.28
1 year 15.2
Extreme 15.2
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
26.5
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Corporate Secretary - 30/08/2024
Corporate Secretary - 30/08/2024
Comptroller/Controller/Auditor 52 18/12/2015
Director TitleAgeSince
Director/Board Member 57 22/02/2017
Director/Board Member 54 28/06/2019
Director/Board Member 54 30/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-5.25%-7.70%-6.49%+23.70% 68Cr
-0.82%-4.60%+145.17%+365.75% 2.19TCr
+0.46%+0.60%-35.58%-20.60% 1.03TCr
+2.78%-4.06%+361.11%+14.06% 803.25Cr
+0.08%-7.53%-32.17% - 700.84Cr
-0.07%-0.01%+82.33%+49.79% 658.01Cr
-0.10%-1.75%-18.67%-20.00% 592.16Cr
-0.21%-1.01%-10.60%-20.90% 438.25Cr
-1.39%+1.62%+74.42%+84.22% 425.76Cr
-0.42%-1.38%-19.61%-27.96% 280.16Cr
Average -0.43%-1.89%+53.99%+49.79% 718.56Cr
Weighted average by Cap. +0.15%-2.49%+85.27%+128.27%

Financials

2024 2025
Net sales 757.48Cr 883.87Cr 112.71Cr 97Cr 92Cr 83Cr 155.99Cr 11TCr 157.16Cr 1.08TCr 420.86Cr 5.44TCr 423.24Cr 413.98Cr 18TCr 718.77Cr 838.7Cr 106.95Cr 92Cr 87Cr 79Cr 148.02Cr 10TCr 149.13Cr 1.03TCr 399.35Cr 5.17TCr 401.61Cr 392.83Cr 17TCr
Net income 41Cr 47Cr 6.05Cr 5.22Cr 4.92Cr 4.48Cr 8.37Cr 571.58Cr 8.44Cr 58Cr 23Cr 292.23Cr 23Cr 22Cr 959.97Cr 33Cr 38Cr 4.87Cr 4.2Cr 3.96Cr 3.61Cr 6.74Cr 460.23Cr 6.79Cr 47Cr 18Cr 235.3Cr 18Cr 18Cr 772.96Cr
Net Debt -11Cr -13Cr -1.62Cr -1.4Cr -1.32Cr -1.2Cr -2.24Cr -153.12Cr -2.26Cr -16Cr -6.05Cr -78Cr -6.09Cr -5.95Cr -257.16Cr 12Cr 14Cr 1.77Cr 1.53Cr 1.44Cr 1.31Cr 2.45Cr 167.04Cr 2.47Cr 17Cr 6.6Cr 85Cr 6.64Cr 6.49Cr 280.54Cr
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,578
Date Price Change Volume
03/26/03 HK$15.71 -5.25% 1,27,000
02/26/02 HK$16.58 -0.12% 68,600
01/26/01 HK$16.60 -0.18% 75,200
31/26/31 HK$16.63 -2.18% 34,000
28/26/28 HK$17.00 -0.12% 46,800

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock